Abstract: A device may receive information regarding a communication session associated with a user device and may determine, based on the received information, a type of communication session associated with the communication session. The device may determine, based on the determined type of communication session, handover parameters associated with the communication session and may transmit the handover parameters to the user device. The device may receive information associated with the signal information for one or more other devices and may initiate, based on the received information, a handover operation associated with the user device.

Abstract: This invention relates to indazole compounds of the structural formula: (structure represented) or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment or amelioration of conditions that could be treated by inhibiting aldosterone synthase.

Abstract: A device may receive information regarding a communication session associated with a user device and may determine, based on the received information, a type of communication session associated with the communication session. The device may determine, based on the determined type of communication session, handover parameters associated with the communication session and may transmit the handover parameters to the user device. The device may receive information associated with the signal information for one or more other devices and may initiate, based on the received information, a handover operation associated with the user device.

Abstract: A two-stage punch accomplishes the two-step process of sheet deformation and nut flaring to attach the nut to the sheet in a single stroke of an assembly press. The punch comprises an outer cylindrical sleeve which captivates a resiliently biased center punch. When the punch is moved downward into contact with the sheet, an embossing ring on the sleeve deforms the sheet material around an aperture in the sheet. When the punch is moved farther downward, a pointed end of the center punch extends beyond the embossing ring and into forcible contact with the nut. The nut is thereby flared capturing the sheet between flared edges of the nut and a nut flange.

Abstract: This invention relates to indazole compounds of the structural formula: (structure represented) or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment or amelioration of conditions that could be treated by inhibiting aldosterone synthase.

Abstract: The present invention relates to (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives having the general formula (I) to pharmaceutical compositions comprising the same and to the use of these (1,1,1,3,3,3-hexafluoro-2-hydroxy-propan-2-yl)phenyl derivatives in the treatment of atherosclerosis.

Abstract: A computer-based detection tool for detecting whether content within a given document is common to content within a plurality of other, existing documents, the detection tool comprising: a character string recognizer for recognizing character strings in the content of the given document; a character string distinguisher for distinguishing main character strings and auxiliary character strings in the recognized character strings by reference to a closed list of main character strings; an encoder for encoding the content of the given document by assigning one or more digits to each main character string and one or more digits to auxiliary character strings; and a matcher for matching a plurality of n-digit streams from within the encoded content with any corresponding n-digit streams within previously-encoded content of the one or more other documents. The character strings may be encoded as a bit-stream.

Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.

Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.

Abstract: The present invention relates to 1-(4-ureidobenzoyl)piperazine derivatives having the general Formula I (We bring to your attention that formula I is not provided on this electronic version as it is provided in the abstract of the paper copy) Wherein R1 is (C1-8)alkyl, (C3-8)cycloalkyl or (C3-8)cycloalkyl(C1-3)alkyl, each of which may be substituted by hydroxy, cyano or halogen; R2 represents 1 or 2 optional halogens; R3 is (C1-6)alkyl, (C3-6)cycloalkyl or (C3-6)cycloalkyl(C1-3)alkyl, each of which may be substituted by one or more halogens; A represents a heteroaryl ring system comprising 1-3 heteroatoms selected from N, O and S, which ring system is 5- or 6-membered when X is C, and 5-membered when X is N; n is 1 or 2; or a pharmaceutically acceptable salt thereof; to pharmaceutical compositions comprising the same, and to the use of a these 1-(4-ureidobenzoyl)piperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholester

Abstract: The present invention provides for compounds of Formulae I and II: wherein 1R, 2R, L, X, q, Z, A, and B have any of the values disclosed in the specification. Compounds of Formulae I and II are useful as reagents to introduce bicyclo[6.1.0]non-4-yne groups into oligonucleotide chains to serve as points of attachment for chemical tags.

Abstract: The present invention relates to hexafluoroisopropanol derivatives having the general formula I to pharmaceutical compositions comprising the same and to the use of these hexafluoroisopropanol derivatives in the treatment of atherosclerosis.

Abstract: The present invention relates to N-benzyl,N?-arylcarbonylpiperazine derivatives having the general formula I to pharmaceutical compositions comprising the same, and to the use of a these N-benzyl,N?-arylcarbonylpiperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholesterol and bile acids transport and metabolism.

Abstract: The present invention relates to (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives having the general formula (I) to pharmaceutical compositions comprising the same and to the use of these (1,1,1,3,3,3-hexafluoro-2-hydroxy-propan-2-yl)phenyl derivatives in the treatment of atherosclerosis.

Abstract: A two-stage punch accomplishes the two-step process of sheet deformation and nut flaring to attach the nut to the sheet in a single stroke of an assembly press. The punch comprises an outer cylindrical sleeve which captivates a resiliently biased center punch. When the punch is moved downward into contact with the sheet, an embossing ring on the sleeve deforms the sheet material around an aperture in the sheet. When the punch is moved farther downward, a pointed end of the center punch extends beyond the embossing ring and into forcible contact with the nut. The nut is thereby flared capturing the sheet between flared edges of the nut and a nut flange.

Abstract: The present invention features methods for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial disease.

Abstract: The present invention features methods for recruitment of bone marrow-derived stem cells (e.g., endothelial cell precursors, hematopoietic stem cells) by administration of nicotine or other nicotine receptor agonist. The methods of the invention can be used in, for example, treatment of conditions amenable to treatment by recruitment of bone marrow-derived stem cells (e.g., neutropenia).

Abstract: The present invention provides ?2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.

Abstract: Embodiments of the present invention relate generally to the field of tissue repair and regeneration. More specifically, embodiments of the present invention relate to medical devices, materials or constructs, such as conductive biocompatible polymers having one or more networks of metal nanowires that enhance tissue repair and regeneration using electromagnetic fields.

Abstract: The present invention provides for compounds of Formula I: wherein L and R1-R6 have any of the values defined there for in the specification. The compounds of formula I are useful as reagents to form folic acid conjugates with hydroxyl-containing compounds of interest, such as oligonucleotides and anti-cancer compounds.